Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Systemic Inflammatory Response Syndrome | 2 | 2025 | 44 | 1.670 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2025 | 12 | 1.210 |
Why?
|
| Vasculitis | 2 | 2022 | 50 | 0.950 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2023 | 4 | 0.840 |
Why?
|
| Arthritis | 1 | 2023 | 53 | 0.810 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2022 | 26 | 0.780 |
Why?
|
| Connective Tissue Diseases | 1 | 2022 | 11 | 0.770 |
Why?
|
| Exanthema | 1 | 2022 | 27 | 0.770 |
Why?
|
| Islets of Langerhans | 1 | 2022 | 279 | 0.680 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2017 | 7 | 0.570 |
Why?
|
| Arthritis, Juvenile | 1 | 2017 | 8 | 0.570 |
Why?
|
| Child | 9 | 2025 | 4488 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2022 | 620 | 0.530 |
Why?
|
| Interleukin-6 | 1 | 2017 | 320 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 234 | 0.490 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2025 | 34 | 0.460 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 869 | 0.410 |
Why?
|
| Th2 Cells | 5 | 2006 | 98 | 0.390 |
Why?
|
| Ovalbumin | 4 | 2006 | 116 | 0.290 |
Why?
|
| Humans | 15 | 2025 | 62947 | 0.270 |
Why?
|
| Th1 Cells | 2 | 2006 | 175 | 0.250 |
Why?
|
| Complement C3 | 1 | 2006 | 59 | 0.250 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2022 | 37 | 0.240 |
Why?
|
| Antigens | 1 | 2006 | 147 | 0.240 |
Why?
|
| Adolescent | 4 | 2022 | 6197 | 0.220 |
Why?
|
| Takayasu Arteritis | 2 | 2020 | 5 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 173 | 0.210 |
Why?
|
| Insulin Antibodies | 1 | 2022 | 2 | 0.200 |
Why?
|
| Glutamate Decarboxylase | 1 | 2022 | 22 | 0.200 |
Why?
|
| Wound Healing | 2 | 2013 | 189 | 0.190 |
Why?
|
| Autoantibodies | 1 | 2022 | 182 | 0.180 |
Why?
|
| Dermatitis, Atopic | 4 | 2005 | 29 | 0.170 |
Why?
|
| Fluconazole | 1 | 2020 | 13 | 0.170 |
Why?
|
| Cryptococcus | 1 | 2020 | 14 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2020 | 127 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 107 | 0.150 |
Why?
|
| Glucose | 1 | 2022 | 470 | 0.150 |
Why?
|
| Cryptococcosis | 1 | 2020 | 79 | 0.150 |
Why?
|
| Infant | 1 | 2023 | 1635 | 0.150 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 70 | 0.140 |
Why?
|
| Mycoplasma Infections | 1 | 2017 | 6 | 0.140 |
Why?
|
| Skin | 4 | 2017 | 377 | 0.140 |
Why?
|
| Mycoplasma | 1 | 2017 | 8 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2017 | 42 | 0.140 |
Why?
|
| Sweet Syndrome | 1 | 2017 | 9 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 298 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 864 | 0.120 |
Why?
|
| Female | 9 | 2022 | 32597 | 0.120 |
Why?
|
| Valerates | 1 | 2013 | 1 | 0.110 |
Why?
|
| Tramadol | 1 | 2013 | 16 | 0.110 |
Why?
|
| Glutamine | 1 | 2013 | 46 | 0.100 |
Why?
|
| Anastomotic Leak | 1 | 2013 | 35 | 0.100 |
Why?
|
| Propofol | 1 | 2013 | 24 | 0.100 |
Why?
|
| Conscious Sedation | 1 | 2013 | 39 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2013 | 66 | 0.100 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 53 | 0.100 |
Why?
|
| Arginine | 1 | 2013 | 124 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1541 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2448 | 0.100 |
Why?
|
| Remission Induction | 1 | 2012 | 147 | 0.090 |
Why?
|
| Lupus Nephritis | 1 | 2012 | 34 | 0.090 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2013 | 125 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2012 | 164 | 0.080 |
Why?
|
| Spleen | 3 | 2006 | 482 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 377 | 0.080 |
Why?
|
| Adult | 3 | 2022 | 16669 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 533 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5608 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2020 | 1973 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 47 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 31 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2006 | 2109 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 31 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 45 | 0.060 |
Why?
|
| Complement C3a | 1 | 2004 | 7 | 0.060 |
Why?
|
| Receptors, Complement | 1 | 2004 | 16 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2158 | 0.060 |
Why?
|
| Male | 8 | 2020 | 29603 | 0.060 |
Why?
|
| Superantigens | 1 | 2003 | 10 | 0.050 |
Why?
|
| Enterotoxins | 1 | 2003 | 21 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2006 | 2181 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2013 | 185 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2004 | 319 | 0.050 |
Why?
|
| Immunization | 1 | 2003 | 133 | 0.050 |
Why?
|
| Dermatomyositis | 1 | 2002 | 6 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2002 | 11 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 33 | 0.050 |
Why?
|
| Animals | 7 | 2013 | 20649 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2005 | 894 | 0.050 |
Why?
|
| Calcinosis | 1 | 2002 | 83 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2002 | 32 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2006 | 981 | 0.050 |
Why?
|
| Polyarteritis Nodosa | 1 | 2001 | 3 | 0.050 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2001 | 13 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 3394 | 0.050 |
Why?
|
| Mice | 5 | 2006 | 10833 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2001 | 34 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2002 | 188 | 0.040 |
Why?
|
| Aorta | 1 | 2001 | 113 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2001 | 185 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2020 | 23 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2020 | 30 | 0.040 |
Why?
|
| Rats | 2 | 2013 | 1982 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 126 | 0.040 |
Why?
|
| Interleukin-4 | 3 | 2005 | 141 | 0.040 |
Why?
|
| Immunoglobulin E | 3 | 2005 | 80 | 0.040 |
Why?
|
| Immunoglobulin G | 3 | 2005 | 467 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 315 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5418 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 1349 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 2013 | 7 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 2013 | 20 | 0.030 |
Why?
|
| Oxidants | 1 | 2013 | 18 | 0.030 |
Why?
|
| Malondialdehyde | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin-5 | 2 | 2004 | 36 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2013 | 165 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 112 | 0.030 |
Why?
|
| Fibrosis | 1 | 2013 | 159 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 227 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 737 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 295 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 252 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 14286 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 554 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 17408 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3262 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 36 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 76 | 0.010 |
Why?
|
| Anaphylatoxins | 1 | 2004 | 1 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 128 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 160 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 568 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 119 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 86 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 80 | 0.010 |
Why?
|
| Mast Cells | 1 | 2002 | 38 | 0.010 |
Why?
|
| Eosinophils | 1 | 2002 | 46 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 1273 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 934 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1536 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 1007 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 1733 | 0.010 |
Why?
|